Fortrea CEO Anshul Thakral to Present at J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Globenewswire
- Executive Participation: Fortrea CEO Anshul Thakral will participate in the J.P. Morgan Annual Healthcare Conference on January 13, 2025, enhancing company transparency and trust among investors through a presentation and Q&A session.
- Investor Relations Enhancement: CFO Jill McConnell and SVP of Investor Relations Tracy Krumme will also attend, aiming to improve investor understanding and confidence in Fortrea, which could stabilize the company's stock price.
- Industry Influence Showcase: As a leading global contract research organization, Fortrea's participation in such key conferences not only highlights its leadership in the life sciences sector but may also attract more potential clients and partners, fostering business growth.
- Clear Market Positioning: By showcasing Fortrea's clinical development solutions at the conference, the company is expected to further solidify its market position in the biopharmaceutical and medical device industries, driving future strategic development.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like FTRE with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on FTRE
Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 15.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
4 Hold
1 Sell
Hold
Current: 16.730
Low
7.00
Averages
15.33
High
25.00
Current: 16.730
Low
7.00
Averages
15.33
High
25.00
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
Continue Reading
Fortrea Updates J.P. Morgan Conference Presentation Time to January 13
- Conference Time Update: Fortrea announces an updated presentation time of 11:15 am PST on January 13, 2026, at the J.P. Morgan Annual Healthcare Conference, featuring CEO Anshul Thakral and CFO Jill McConnell, highlighting the company's leadership in clinical development.
- Investor Engagement: The conference will offer live streaming and replays accessible through the 'Events' section of Fortrea's Investor Relations website, enhancing communication and transparency with investors.
- Industry Position: As a leading global contract research organization, Fortrea provides clinical development solutions across over 20 therapeutic areas, showcasing its capability in driving healthcare innovation and accelerating therapies to patients.
- Global Reach: Operating in approximately 100 countries, Fortrea leverages three decades of experience and a robust investigator network to deliver agile solutions to clients, further solidifying its market position in the life sciences sector.
Continue Reading